Icariin inhibits prostate cancer bone metastasis and destruction via suppressing TAM/CCL5-mediated osteoclastogenesis
Authors:
- Shengqi WangSWShengqi Wang
- Neng WangNWNeng Wang
- Yifeng ZhengYZYifeng Zheng
- Zhiyu WangZWZhiyu Wang
- Songtao XiangSXSongtao Xiang
- 10 September 2023
- journal article
- research article
- Published by Elsevier in Phytomedicine
- Vol. 120, 155076
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysisSpringerPlus, 2016
- Icariin protects against titanium particle-induced osteolysis and inflammatory response in a mouse calvarial modelBiomaterials, 2015
- PDGFB-based stem cell gene therapy increases bone strength in the mouseProceedings of the National Academy of Sciences, 2015
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate CancerEuropean Urology, 2014
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-κB regulated HIF-1α and PGE2 synthesisPhytomedicine, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Skeletal Related Events, Bone Metastasis and Survival of Prostate Cancer: A Population Based Cohort Study in Denmark (1999 to 2007)Journal of Urology, 2010
- Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potentialCytotherapy, 2004
- A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate CarcinomaJNCI: Journal of the National Cancer Institute, 2002